New RSV vaccine shows promise for transplant patients

NCT ID NCT05921903

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 14, 2026

Summary

This study tested an experimental RSV vaccine in 386 adults, including lung and kidney transplant recipients and healthy older adults. The goal was to see if the vaccine triggers a strong immune response and is safe for people with weakened immune systems. Researchers compared one dose versus two doses in transplant recipients to find the best approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Phoenix, Arizona, 85013, United States
GSK Investigational Site

Chicago, Illinois, 60612, United States
GSK Investigational Site

Lexington, Kentucky, 40536, United States
GSK Investigational Site

Minneapolis, Minnesota, 55455, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

Omaha, Nebraska, 68198-2456, United States
GSK Investigational Site

New York, New York, 10032, United States
GSK Investigational Site

New York, New York, 10065, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15213, United States
GSK Investigational Site

Temple, Texas, 76502, United States
GSK Investigational Site

Camperdown, New South Wales, 2050, Australia
GSK Investigational Site

Birtinya, Queensland, 4556, Australia
GSK Investigational Site

Herston, Queensland, 4029, Australia
GSK Investigational Site

Adelaide, South Australia, 5000, Australia
GSK Investigational Site

Edmonton, Alberta, T6G 2B7, Canada
GSK Investigational Site

Vancouver, British Columbia, V5Z 1M9, Canada
GSK Investigational Site

London, Ontario, N6A 5A5, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2N2, Canada
GSK Investigational Site

Sherbrooke, Quebec, J1J 2G2, Canada
GSK Investigational Site

Giessen, 35392, Germany
GSK Investigational Site

Milan, 20122, Italy
GSK Investigational Site

Milan, 20132, Italy
GSK Investigational Site

Palermo, 90127, Italy
GSK Investigational Site

Pavia, 27100, Italy
GSK Investigational Site

Siena, 53100, Italy
GSK Investigational Site

Aichi, 466-8650, Japan
GSK Investigational Site

Aichi, 470-1192, Japan
GSK Investigational Site

Fukuoka, 814-0180, Japan
GSK Investigational Site

Hyōgo, 662-0918, Japan
GSK Investigational Site

Kumamoto, 861-8520, Japan
GSK Investigational Site

Okayama, 700-8558, Japan
GSK Investigational Site

Tokyo, 160-0017, Japan
GSK Investigational Site

Tokyo, 193-0998, Japan
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Seoul, 110-774, South Korea
GSK Investigational Site

Seoul, 138-736, South Korea
GSK Investigational Site

A Coruña, 15006, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Santander, 39011, Spain

Conditions

Explore the condition pages connected to this study.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS